Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (GB:0HD2)
LSE:0HD2
Alnylam Pharma (0HD2) Share Price & Analysis
1 Followers
0HD2 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$143.66 - $217.98
Previous Close$147.39
Volume249.00
Average Volume (3M)815.00
Market Cap
$18.60B
Enterprise Value$17.47B
Total Cash (Recent Filing)$2.44B
Total Debt (Recent Filing)$1.31B
Price to Earnings (P/E)N/A
Beta0.57
Next Earnings
Apr 25, 2024EPS Estimate
-$1.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding125,945,793
10 Day Avg. Volume45
30 Day Avg. Volume815
Standard Deviation0.15
R-Squared0.04
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)-84.31
Price to Sales (P/S)42.92
Price to Cash Flow (P/CF)-156.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue9.62
Enterprise Value/Gross Profit11.20
Enterprise Value/Ebitda-64.86
Forecast
1Y Price Target
$223.33Price Target Upside51.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering21
Alnylam Pharma News
PremiumCompany Announcements
Alnylam Pharmaceuticals Finalizes Exit Deal with EVP Franchini
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the KARDIA-3 trial for zilebesiran in high-risk cardiovascular patients highlights the drug's advancement in clinical development and its potential to meet significant unmet medical needs.
Drug EfficacyZilebesiran achieved clinically meaningful and significant reductions in blood pressure lasting for six months, showing sustained efficacy and potential for better patient outcomes.
Strategic PartnershipsThe strategic collaboration with Roche, which includes a significant financial package, has the potential to strengthen Alnylam's financial position and accelerate zilebesiran's development and commercialization.
Bears Say
Clinical Trial ResultsThe effect size of zilebesiran was less robust on top of olmesartan with only a 4.0 mmHg reduction.
Sales PerformanceOnpattro sales were down 11% quarter over quarter, indicating high cannibalization by next-gen Amvuttra.
Trial Enrollment ConcernsA reduction in enrolled patients may decrease the statistical power of the HELIOS-B trial, which is a concern for investors.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.11% Other Institutional Investors
99.89% Public Companies and
Individual Investors
0HD2 FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest share price was $143.66 and its highest was $217.98 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Currently, no data Available
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is Apr 25, 2024 which is in 5 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Feb 15, 2024. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.186 by $0.086.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -$1.14.
How many shares outstanding does Alnylam Pharmaceuticals have?
Currently, no data Available
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.186. Following the earnings report the stock price went down -8.284%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Among the largest hedge funds holding Alnylam Pharmaceuticals’s share is Dodge & Cox. It holds Alnylam Pharmaceuticals’s shares valued at 703M.
---
Alnylam Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$223.33 (51.52% Upside)
$223.33 (51.52% Upside)
Blogger Sentiment
Bullish
GB:0HD2 Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
7.99%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
---
0HD2 Company Deck
---
0HD2 Earnings Call
Q4 2024
0:00 / 0:00
---
0HD2 Stock 12 Months Forecast
Average Price Target
$223.33
▲(51.52% Upside)
Technical Analysis
Alnylam Pharma
―
Arrowhead Pharmaceuticals
―
Crispr Therapeutics AG
―
Editas Medicine
―
Intellia Therapeutics
―
Best Analysts Covering 0HD2
1 Year
1 Year Success Rate
20/33 ratings generated profit
1 Year Average Return
+18.21%
reiterated a buy rating 2 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 60.61% of your transactions generating a profit, with an average return of +18.21% per trade.
---